New York, January 10, 2026, 19:54 EST — The market has closed.
- CG Oncology shares surged roughly 29% on Friday following an update on the timing of their Phase 3 trial
- Company now targets PIVOT-006 topline data in H1 2026, almost a full year ahead of schedule
- Morgan Stanley raised its price target to $93, pointing to the faster-than-expected readout
CG Oncology Inc (CGON) shares surged nearly 29% on Friday, closing at $54.20 after hitting a session high of $57.36. The stock gained $12.25 during the day on volume of about 7.0 million shares.
CG Oncology said it now expects “topline” Phase 3 results—the initial look at main trial endpoints—in the first half of 2026, almost a year earlier than planned. For a clinical-stage biotech, accelerating a key readout can shift investor expectations and company valuations. Nasdaq
The PIVOT-006 trial, which tests an adjuvant therapy versus surveillance after tumor removal in intermediate-risk non-muscle invasive bladder cancer (NMIBC), is moving ahead faster than expected. CG Oncology credited the quicker timeline to rapid enrollment at over 90 clinical sites. The company noted that the U.S. intermediate-risk patient pool tops 50,000. Investing.com
A Friday regulatory filing outlined PIVOT-006 as a randomized registrational study involving over 360 patients. The term “intravesical” indicates the therapy is administered directly into the bladder. NMIBC refers to disease that hasn’t invaded the muscle layer of the bladder. SEC
Chief Executive Arthur Kuan said the company aims to accelerate a potential adjuvant indication in intermediate-risk NMIBC, “for which there are currently no U.S. FDA approved options.” He also highlighted early enrollment completion and strong participation from both academic and community sites. SEC
Morgan Stanley bumped up its price target on CG Oncology to $93 from $89, keeping an Overweight rating in place, according to a Friday report by Investing.com. Analyst Jeffrey Hung noted that the faster timeline points to “strong execution” and “high physician engagement,” the report added.
In a fresh slide deck submitted to the SEC, the company confirmed that topline data for PIVOT-006 is due in the first half of 2026 and detailed more milestones for its NMIBC program that year. The presentation also noted NCCN guidelines have dropped BCG therapy for intermediate-risk patients, citing shortages. SEC
Bladder-sparing treatments are already fighting for ground in high-risk, BCG-unresponsive NMIBC. The FDA has greenlit Merck’s Keytruda, Ferring’s Adstiladrin, and ImmunityBio’s Anktiva (used alongside BCG). CG Oncology aims to break into the intermediate-risk segment, claiming approved therapies there are scarce.
U.S. markets are closed for the weekend, leaving traders to see if Friday’s sharp move carries into Monday’s session. Early volume and options activity usually help set the tone for small-cap biotechs following a catalyst-driven jump.
The accelerated timeline doesn’t change the main risk: cretostimogene is still investigational, and a Phase 3 failure could wipe out gains in a flash. Regulators might also challenge endpoints, durability data, or the overall submission package.
The next major catalyst remains the PIVOT-006 topline results, slated for the first half of 2026. Without a firmer timeline from the company, traders will probably focus on CGON shares reacting to trial progress reports and any new details emerging ahead of that readout.
